Palifermin
- Generic Name
- Palifermin
- Brand Names
- Kepivance
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 162394-19-6
- Unique Ingredient Identifier
- QMS40680K6
- Background
Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli.
Palifermin was granted FDA approval on 15 December 2004.
- Indication
For treatment of oral mucositis associated with chemotherapy and radiation therapy.
- Associated Conditions
- Oral Mucositis
- Associated Therapies
- -
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
Phase 1
Recruiting
- Conditions
- Myelodysplastic SyndromeAcute Lymphoblastic LeukemiaSecondary Acute Myeloid LeukemiaAcute Myeloid Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationBiological: BasiliximabDrug: Fludarabine PhosphateDrug: Indium In 111-DOTA-BasiliximabDrug: MelphalanBiological: PaliferminRadiation: Total Lymphoid IrradiationRadiation: Total Marrow IrradiationBiological: Yttrium Y 90 Basiliximab
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT05139004
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath